135 related articles for article (PubMed ID: 25756508)
1. Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer.
Holder SL; Drabick J; Zhu J; Joshi M
Cancer Biol Ther; 2015; 16(2):207-9. PubMed ID: 25756508
[TBL] [Abstract][Full Text] [Related]
2. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
Venkitaraman R; Lorente D; Murthy V; Thomas K; Parker L; Ahiabor R; Dearnaley D; Huddart R; De Bono J; Parker C
Eur Urol; 2015 Apr; 67(4):673-9. PubMed ID: 25457497
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.
Mehra N; Sharp A; Lorente D; Dolling D; Sumanasuriya S; Johnson B; Dearnaley D; Parker C; de Bono J
Clin Genitourin Cancer; 2017 Dec; 15(6):678-684.e1. PubMed ID: 28606735
[TBL] [Abstract][Full Text] [Related]
4. Reply from authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in prostate cancer: the jury is still out... and even more confused. Eur Urol 2015;67:680-1: Corticosteroids in prostate cancer: known benefits versus potential risks.
Parker C; De Bono J
Eur Urol; 2015 Apr; 67(4):681-2. PubMed ID: 25442054
[No Abstract] [Full Text] [Related]
5. Steroids in prostate cancer: the jury is still out... and even more confused.
Porta C; Bracarda S; Danesi R
Eur Urol; 2015 Apr; 67(4):680-1. PubMed ID: 25465980
[No Abstract] [Full Text] [Related]
6. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
Lorente D; Omlin A; Ferraldeschi R; Pezaro C; Perez R; Mateo J; Altavilla A; Zafeirou Z; Tunariu N; Parker C; Dearnaley D; Gillessen S; de Bono J; Attard G
Br J Cancer; 2014 Dec; 111(12):2248-53. PubMed ID: 25314055
[TBL] [Abstract][Full Text] [Related]
7. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Shiga KI; Koga H; Yamaguchi A; Naito S; Eto M
BJU Int; 2016 Dec; 118(6):880-884. PubMed ID: 26991851
[TBL] [Abstract][Full Text] [Related]
8. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
11. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer.
Venkitaraman R; Thomas K; Huddart RA; Horwich A; Dearnaley DP; Parker CC
BJU Int; 2008 Feb; 101(4):440-3. PubMed ID: 17941935
[TBL] [Abstract][Full Text] [Related]
13. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Rothermundt C; Hayoz S; Templeton AJ; Winterhalder R; Strebel RT; Bärtschi D; Pollak M; Lui L; Endt K; Schiess R; Rüschoff JH; Cathomas R; Gillessen S
Eur Urol; 2014 Sep; 66(3):468-74. PubMed ID: 24412228
[TBL] [Abstract][Full Text] [Related]
14. [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
Fukui T; Nakamura K; Sakatani T; Atsuta T; Kato T; Fukumoto T; Ito M; Inoue K; Terai A
Hinyokika Kiyo; 2017 Feb; 63(2):57-62. PubMed ID: 28264534
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
16. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Fukuta F; Kitamura H; Yanase M; Taguchi K; Takahashi A; Kunishima Y; Miyake M; Adachi H; Itoh N; Hirose T; Takagi S; Miyao N; Matsukawa M; Shigyo M; Masumori N
Jpn J Clin Oncol; 2015 Jul; 45(7):682-7. PubMed ID: 25862824
[TBL] [Abstract][Full Text] [Related]
19. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients.
Biró K; Budai B; Szőnyi M; Küronya Z; Gyergyay F; Nagyiványi K; Géczi L
Urol Oncol; 2018 Feb; 36(2):81.e1-81.e7. PubMed ID: 29153623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
